摘要
目的探讨血必净联合利奈唑胺治疗重症肺炎患者的临床疗效。方法选取2018年1月至2020年7月本院收治的50例重症肺炎患者作为研究对象,按照随机数字表法分为两组,每组25例。对照组给予利奈唑胺治疗,观察组在对照组基础上给予血必净治疗,比较两组临床指标(咳嗽症状改善时间、通气情况改善时间、住院时间)、临床疗效、细菌清除率和治疗前后血气指标[动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))、血氧饱和度(SaO_(2))、氧合指数(OI)]、感染指标[降钙素原(PCT)、白细胞介素-6(IL-6)和C反应蛋白(CRP)]。结果观察组咳嗽症状改善时间、通气情况改善时间、住院时间均短于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率(88.00%)高于对照组(68.00%),差异有统计学意义(P<0.05)。观察组细菌清除率(100.00%)高于对照组(80.00%),差异有统计学意义(P<0.05)。治疗前,两组PaCO_(2)、PaO_(2)、SaO_(2)、OI比较差异无统计学意义;治疗后,两组PaCO_(2)低于治疗前,PaO_(2)、SaO_(2)、OI均高于治疗前,且观察组PaCO_(2)低于对照组,PaO_(2)、SaO_(2)、OI均高于对照组,差异有统计学意义(P<0.05)。治疗前,两组PCT、IL-6和CRP水平比较差异无统计学意义;治疗后,两组PCT、IL-6和CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论利奈唑胺联合血必净治疗重症肺炎效果确切,可有效改善患者的肺部炎症反应及血气指标,提高细菌清除率和临床疗效,缩短症状改善时间及住院时间,促进患者尽快康复,值得临床推广应用。
Objective To explore the clinical efficacy of Xubijing combined with linezolid in the treatment of patients with severe pneumonia.Methods 50 patients with severe pneumonia admitted to our hospital from January 2018 to July 2020 were selected as the study subjects,and they were divided into two groups according to random number table method,with 25 cases in each group.The control group was given linezolid treatment,and the observation group was given Xuebijing treatment on the basis of the control group.The clinical indexes(cough symptom improvement time,ventilation improvement time,hospitalization time),clinical efficacy,bacterial clearance,blood gas indexes(arterial partial pressure of carbon dioxide[PaCO_(2)],arterial partial pressure of oxygen[PaO_(2)],blood oxygen saturation[SaO_(2)],oxygenation index[OI]),infection indexes(procalcitonin[PCT],interleukin-6[IL-6]and C-reactive protein[CRP])before and after treatment were compared between the two groups.Results The cough symptom improvement time,ventilation improvement time and hospitalization time in the observation group were shorter than those in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment of the observation group(88.00%)was higher than that of thecontrol group(68.00%),and the difference was statistically significant(P<0.05).The bacterial clearance rate of the observation group(100.00%)was higher than that of the control group(80.00%),and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in PaCO_(2),PaO_(2),SaO_(2),OI between the two groups.After treatment,the PaCO_(2) of the two groups was lower than that before treatment,PaO_(2),SaO_(2) and OI were all higher than those before treatment,and the PaCO_(2) in the observation group was lower than that in the control group,PaO_(2),SaO_(2) and OI were all higher than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significa
作者
杨俊明
YANG Junming(Department of Critical Care medicine,Yuxi People's Hospital,Yuxi,Yunnan,653100,China)
出处
《当代医学》
2022年第14期21-24,共4页
Contemporary Medicine
关键词
血必净
利奈唑胺
重症肺炎患者
细菌清除率
血气指标
Xuebijing
Linezolid
Patients with severe pneumonia
Bacterial clearance rate
Blood gas index
